Skip to main content

High sensitivity C-Reactive Protein in Chronic heart failure: Patient Characteristics, Phenotypes and mode of death (2019)
Journal Article
Pellicori, P., Zhang, J., Cuthbert, J., Urbinati, A., Shah, P., Kazmi, S., …Cleland, J. (in press). High sensitivity C-Reactive Protein in Chronic heart failure: Patient Characteristics, Phenotypes and mode of death. Cardiovascular research, https://doi.org/10.1093/cvr/cvz198

Aims: Plasma concentrations of high sensitivity C-reactive protein (hsCRP) are often raised in chronic heart failure (CHF) and might indicate inflammatory processes that could be a therapeutic target. We aimed to study the associations between hsCRP,... Read More about High sensitivity C-Reactive Protein in Chronic heart failure: Patient Characteristics, Phenotypes and mode of death.

What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? (2017)
Journal Article
Pellicori, P., Urbinati, A., Shah, P., MacNamara, A., Kazmi, S., Dierckx, R., …Clark, A. L. (2017). What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?. European journal of heart failure, 19(6), 768-778. https://doi.org/10.1002/ejhf.788

Aims The PARADIGM-HF trial showed that sacubitril–valsartan, an ARB–neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF). It is uncertain what proportion of patients with HF would be eligible for sacubitril... Read More about What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?.


;